Physician profile
Omer Khalil
NPI 1467671792
$630.78
in general payments reported to CMS, 2019-2025
13 companies · $13.56 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $74.99 · 2021: $118 · 2022: $25.90 · 2023: $91.76 · 2024: $92.17 · 2025: $13.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $134 · Food and Beverage: $63.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $134.24 |
| Food and Beverage | $63.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $169.99 | 2020-2021 | |
| Astellas Pharma US INC | $95.00 | 2019 | |
| Pfizer INC. | $94.53 | 2019-2025 | |
| Kyowa Kirin, INC. | $63.20 | 2019 | |
| Apellis Pharmaceuticals, INC. | $45.76 | 2023 | Empaveli |
| Merck Sharp & Dohme LLC | $33.51 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $25.95 | 2024 | Enhertu |
| Acrotech Biopharma INC. | $25.90 | 2022 | |
| Amgen INC. | $20.81 | 2019 | |
| Agios Pharmaceuticals, INC. | $16.53 | 2024 | Pyrukynd |
| Janssen Biotech, INC. | $16.18 | 2024 | Carvykti |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Epizyme, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omer Khalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.